Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

ITCI has been the subject of several other reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.53 on Thursday. Intra-Cellular Therapies has a one year low of $64.09 and a one year high of $131.57. The company has a market cap of $13.99 billion, a P/E ratio of -151.18 and a beta of 0.69. The firm has a 50 day simple moving average of $126.89 and a two-hundred day simple moving average of $96.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, analysts expect that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several large investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Intra-Cellular Therapies in the 4th quarter valued at about $268,347,000. Raymond James Financial Inc. purchased a new stake in Intra-Cellular Therapies in the 4th quarter valued at about $76,451,000. Adage Capital Partners GP L.L.C. increased its stake in Intra-Cellular Therapies by 266.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company’s stock valued at $56,627,000 after buying an additional 493,000 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after buying an additional 402,186 shares during the last quarter. Finally, Deep Track Capital LP increased its stake in Intra-Cellular Therapies by 24.9% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $167,040,000 after buying an additional 399,307 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.